BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/27/2023 1:26:07 AM | Browse: 531 | Download: 1964
Publication Name World Journal of Clinical Cases
Manuscript ID 84337
Country China
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Clinical Trials Study
Article Title Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2 diabetes mellitus treatment: A phase 2 clinical trial
Manuscript Source Unsolicited Manuscript
All Author List Xiao-Fen Lian, Dong-Hui Lu, Hong-Li Liu, Yan-Jing Liu, Yang Yang, Yuan Lin, Feng Xie, Cai-Hao Huang, Hong-Mei Wu, Ai-Mei Long, Chen-Jun Hui, Yu Shi, Yun Chen, Yun-Feng Gao and Fan Zhang
ORCID
Author(s) ORCID Number
Xiao-Fen Lian http://orcid.org/0000-0001-7950-8867
Dong-Hui Lu http://orcid.org/0000-0001-9172-2989
Hong-Li Liu http://orcid.org/0000-0002-2601-2857
Yan-Jing Liu http://orcid.org/0000-0003-0489-3769
Yang Yang http://orcid.org/0000-0002-1200-8072
Yuan Lin http://orcid.org/0000-0003-4623-2096
Feng Xie http://orcid.org/0000-0002-6482-272X
Cai-Hao Huang http://orcid.org/0000-0002-2116-9724
Hong-Mei Wu http://orcid.org/0000-0002-3054-0345
Ai-Mei Long http://orcid.org/0000-0002-4173-8445
Yu Shi http://orcid.org/0000-0002-3918-0630
Yun Chen http://orcid.org/0000-0002-4975-5637
Yun-Feng Gao http://orcid.org/0000-0003-3503-7359
Fan Zhang http://orcid.org/0000-0001-5147-663X
Funding Agency and Grant Number
Funding Agency Grant Number
Shenzhen Science and Technology Innovation Committee Projects JCYJ20170816105416349
Shenzhen High-Level Hospital Construction Fund
Shenzhen Key Medical Discipline Construction Fund SZXK010
Corresponding Author Fan Zhang, MD, Doctor, Doctor, Department of Endocrinology, Peking University Shenzhen Hospital, LianHua Road, Shenzhen 518000, Guangdong Province, China. bjdxszyynfm@163.com
Key Words Type 2 diabetes mellitus; Cell transplantation; Human umbilical cord-mesenchymal stem cells; Safety; Lymphocytes; Immunity
Core Tip Diabetes mellitus is a major public health problem worldwide. Type 2 diabetes mellitus is regarded as a chronic progressive disease that arises from an impairment in the insulin-sensing mechanisms culminating in insulin resistance. Our article focused on the safety of human umbilical cord mesenchymal stem cell infusion for treating type 2 diabetes mellitus. The results suggested that human umbilical cord mesenchymal stem cell treatment can impact human immunity and inhibit lymphocytes. We should pay attention to its influence on coagulation.
Publish Date 2023-07-27 01:26
Citation Lian XF, Lu DH, Liu HL, Liu YJ, Yang Y, Lin Y, Xie F, Huang CH, Wu HM, Long AM, Hui CJ, Shi Y, Chen Y, Gao YF, Zhang F. Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2 diabetes mellitus treatment: A phase 2 clinical trial. World J Clin Cases 2023; 11(21): 5083-5096
URL https://www.wjgnet.com/2307-8960/full/v11/i21/5083.htm
DOI https://dx.doi.org/10.12998/wjcc.v11.i21.5083
Full Article (PDF) WJCC-11-5083-with-cover.pdf
Full Article (Word) WJCC-11-5083.docx